Archived: Interim Statement on the Use of the rVSVΔG-ZEBOV-GP Vaccine for the Prevention of Ebola Virus Disease

ASEM 文献综述

Official National Advisory Committee on Immunization document (2020) on “Archived: Interim Statement on the Use of the rVSVΔG-ZEBOV-GP Vaccine for the Prevention of Ebola Virus Disease”. Merck’s investigational rVSVΔG-ZEBOV-GP vaccine is a live-attenuated, recombinant vesicular stomatitis virus (rVSV)-based vector vaccine against Zaire ebolavirus (ZEBOV).

此摘要有助于您识别文档。对于临床建议，请始终查阅官方现行版本及其更新日期。